Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02280876

Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) (PCNS-EM)

Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).

Sponsor: Comisión Nacional de Investigación Científica y Tecnológica

Conditions Multiple Sclerosis, Relapsing-Remitting

Interventions 1 - Andrographis paniculata p/st extract 2 - Excipients

Updated 5 times since 2017 Last updated: Jun 21, 2016 Started: Jan 31, 2012 Primary completion: Feb 28, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Multiple Sclerosis, Relapsing-Remitting and is currently completed. Comisión Nacional de Investigación Científica y Tecnológica leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Comisión Nacional de Investigación Científica y Tecnológica
Universidad Austral de Chile
University of Chile

Data source: Universidad Austral de Chile

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valdivia, Chile